Soledad Cuenca Miranda

All filings by Soledad Cuenca Miranda on record concern Pharma Mar, S.A., in the capacity of board member. Between 1 April 2025 and 17 June 2026, the trades on record add up to 7 filings.

In open-market terms, that means 5 purchases worth €43k on one side and 1 sale worth €6,600 on the other. Purchases outweigh sales by €37k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 2 purchases and 1 sale.

Half of the purchases are above €6,075 and half below. Scaled by market value, the purchases weigh a median 0.0004% of market cap (sample: 5 purchases). Clusters matter here: 2 out of 5 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 5 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 60% of cases, with a median move of +6.6%. This is a record of the past, not a forecast.

The latest filing, published on 17 June 2026, reports a transaction in Pharma Mar, S.A. The last insider purchase was made public on 24 March 2026, 208 days ago. Filings reach the CNMV feed a median of 2 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by CNMV. They describe what insiders did and are not a recommendation.